SIGNIA THERAPEUTICS RECEIVES A €1.7 MILLION DEEPTECH DEVELOPMENT GRANT FROM BPIFRANCE
January 05, 2022
With a total budget of €3.7 million over 36 months, the supported program aims to scale up the SIGNATURA drug ...
Read more
SIGNIA THERAPEUTICS obtains EUROPEAN FUNDING in recognition of its major achievements and to ACCELERATE THE DEVELOPMENT OF ITS SIGNATURA® PLATFORM
May 27, 2020
LYON, FRANCE (May 27, 2020) - Signia Therapeutics announced today that it has received a grant of € 2.38 millionfrom the E ...
Read more
Signia Therapeutics will be present at JP Morgan Healthcare Conference (Jan 13-15th 2020)
January 09, 2020
SIGNIA THERAPEUTICS will be in San Francisco fo ...
Read more
Signia Therapeutics, Cynbiose and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project
December 09, 2019
Signia Therapeutics, Cynbiose and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project to adv ...
Read more
Appointment of a Chief Business officer for Signia Therapeutics
November 18, 2019
Appointment of a Chief Business officer for Signia Therapeutics It is with a great pleasure that Signia Therapeutics announces the ar ...
Read more
Signia Therapeutics to be present at the Options for the Control of Influenza X Conference
August 20, 2019
Very pleased to announce that Dr. Andrés Pizzorno - Signia Therapeutics’ cofounder and Project Manager - has been invited by the Sc ...
Read more
Signia Therapeutics awarded with the label “French Tech Seed”
March 15, 2019
Signia Therapeutics is very proud to announce it has been awarded with the label “French Tech Seed” by a wide and independent eval ...
Read more
Signia Therapeutics to present at the 2nd i4iD – Immunotherapies for infectious Diseases – conference
November 21, 2018
Signia Therapeutics announces it has been selected to present its strategy based on clinical gene expression infection signatures to t ...
Read more
Signia Therapeutics to present preclinical results at the 6th ISIRV-AVG Antiviral Conference
November 09, 2018
Signia Therapeutics announces it has been invited to present company and update of development at the upcoming 6th ISIRV-AVG “Advan ...
Read more
Signia Therapeutics announces an agreement with SANOFI to evaluate potential pipeline candidates
November 01, 2018
Signia Therapeutics announces an agreement with SANOFI to evaluate potential pipeline candidates LYON, FRANCE (November 1, 2018) ...
Read more
Signia Therapeutics announces the nomination of a CEO
October 29, 2018
Signia Therapeutics announces the nomination of Dr. Philippe Personne as CEO, effective as of 1st of October. Dr. Personne graduate ...
Read more